Evidence · Randomised trial
Phase I randomized clinical trial of N-acetylcysteine in combination with an adjuvant probenecid for treatment of severe traumatic brain injury in children.
- Medical
- Neurology
- Raised intracranial pressure
- Trauma and burns
- Traumatic brain injury
This paper is from 2017, more than five years ago. Newer evidence may have been published since.
Summary
Phase I randomised, double-blind, placebo-controlled trial of oral/enteral N-acetylcysteine plus probenecid in 14 children aged 2-18 years admitted to PICU with severe traumatic brain injury and an externalised ventricular drain. Serum and CSF drug concentrations were measured to confirm CNS penetration, and safety was the primary focus. No adverse events were attributed to the drug combination, and physiological measures, ICP-directed therapy use, injury biomarkers and 3-month Glasgow Outcome Scale did not differ between groups. Of interest to PICU clinicians as early-phase neuroprotection research rather than practice guidance.
Summary written for PICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to PICUlearn members, and Peeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.